Related Experiment Video

Updated: Jul 11, 2025

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

15.8K

Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?

Kenneth J C Lim1, Robin Filshie1

  • 1St Vincent's Hospital Melbourne, Melbourne, VIC, 3065 Australia.

The Lancet. Haematology
|November 3, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.3K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K

Related Experiment Videos

Last Updated: Jul 11, 2025

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

15.8K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.3K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

96
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
96

Articles linked to this work by shared authors, journal, and citation graph.

Review Article: Immune Effector Cell-Mediated Enterocolitis Following CAR-T Cell Therapy-Clinical Features, Pathophysiology and Management.

Alimentary pharmacology & therapeutics·2026

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.

American journal of hematology·2026

Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups.

Clinical lymphoma, myeloma & leukemia·2026

Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma.

Blood cancer journal·2025

Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia·2025

ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL.

Blood advances·2025

High time for risk-adapted treatment in mantle cell lymphoma.

The Lancet. Haematology·2026

Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers.

The Lancet. Haematology·2026

Beyond maximum grade: key regulatory considerations in adverse event reporting.

The Lancet. Haematology·2026

Beyond maximum grade: long-term toxicity and survivorship in haematological malignancies.

The Lancet. Haematology·2026

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

The Lancet. Haematology·2026

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial.

The Lancet. Haematology·2026

Necrosis or Related Skin Changes After Subcutaneous Injection of Buprenorphine Extended-Release: A Case Series.

International journal of addiction nursing·2026

Natural language processing-based model to predict radiation pneumonitis in patients with locally advanced non-small cell lung cancer undergoing chemoradiotherapy: a retrospective cohort study.

EClinicalMedicine·2026

Quality assurance for deep learning-based proton therapy planning in routine clinical use for oropharyngeal cancer.

Physics and imaging in radiation oncology·2026

Self-rolling film for in vivo drug delivery to limit colonic inflammation induced after radiation exposure.

iScience·2026

Predicting the benefit of adaptive radiotherapy in head and neck Cancer using cone-beam computed tomography.

Physics and imaging in radiation oncology·2026

Sunitinib-Induced Hand-Foot Skin Reaction: A Case Report.

Cureus·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us